[Federal Register Volume 64, Number 198 (Thursday, October 14, 1999)] [Notices] [Pages 55735-55736] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 99-26719] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 99D-4054] Draft Guidance for Industry on Intraocular Lens; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of the draft guidance entitled ``Intraocular Lens Guidance Document.'' This draft guidance is not final nor is it in effect at this time. This draft guidance describes preclinical and clinical requirements that may be used in support of investigational device exemptions, premarket approval applications, and product development protocols. This draft guidance describes for industry and FDA reviewers the type of information needed to support investigational and marketing applications for intraocular lenses. DATES: Written comments concerning this guidance must be received by January 12, 2000. ADDRESSES: Submit written requests for single copies on a 3.5'' diskette of the draft guidance entitled ``Intraocular Lens Guidance Document'' to the Division of Small Manufacturers Assistance (HFZ-220), Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850. Send two self- addressed adhesive labels to assist that office in processing your request, or fax your request to 301-443-8818. Written comments concerning this draft guidance must be submitted to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Comments should be identified with the docket number found in the brackets in the heading of this document. See the SUPPLEMENTARY INFORMATION section for information on electronic access to this draft guidance. FOR FURTHER INFORMATION CONTACT: Donna R. Lochner, Center for Devices and Radiological Health (HFZ-463), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2053. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a draft guidance entitled ``Intracular Lens Guidance Document.'' This draft guidance provides detailed information about the type of preclinical testing needed to support both a clinical investigation and marketing applications for new intraocular lenses and modifications to intraocular lenses. This draft guidance also provides the basic principles that should be applied in the conduct of a clinical study for new or modified intraocular lenses. Earlier revisions of this draft guidance have been discussed in numerous forums since April of 1997, and industry, clinicians, and other interested parties have participated. These forums have included at least three Ophthalmic Device Panel meetings at which this draft guidance, or parts of the guidance, have been discussed. These Panel discussions began before 1997, and most recently they occurred in October 1997. Both written and verbal comments have been received and discussed thoroughly in these forums. Although this draft guidance, to a large extent, describes review elements that have been in existence since almost the inception of FDA's review of intraocular lenses, it has been refined and improved through the interactive discussions with the industry, clinicians, panel members, and other interested parties. FDA has made available to all interested parties a summary of all written comments received, and on each version of the guidance FDA has noted the changes from the previous version. This information is available for this most recent release and for previous revisions. Interested persons may obtain this information through the contact person at the address and phone number given above. II. Significance of Guidance This draft guidance document represents the agency's current thinking on submissions for intraocular lenses. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both. The agency has adopted Good Guidance Practices (GGP's), which set forth the agency's policies and procedures for the development, issuance, and use of guidance documents (62 FR 8961, February 27, 1997). This guidance document is [[Page 55736]] issued as a Level 1 guidance consistent with GGP's. III. Electronic Access In order to receive the ``Intraocular Lens Guidance Document'' via your fax machine, call the CDRH Facts-On-Demand (FOD) system at 800- 899-0381 or 301-827-0111 from a touch-tone telephone. At the first voice prompt press 1 to access DSMA Facts, at second voice prompt press 2, and then enter the document number (834) followed by the pound sign (#). Then follow the remaining voice prompts to complete your request. Persons interested in obtaining a copy of the guidance may also do so using the World Wide Web (WWW). The Center for Devices and Radiological Health (CDRH) maintains an entry on the WWW for easy access to information, including text, graphics, and files that may be downloaded to a personal computer with access to the WWW. Updated on a regular basis, the CDRH Home Page includes the ``Intraocular Lens Guidance Document,'' device safety alerts, Federal Register reprints, information on premarket submissions (including lists of approved applications and manufacturers' addresses), small manufacturers' assistance, information on video conferencing and electronic submissions, mammography matters, and other device-oriented information. The CDRH home page may be accessed at ``http:// www.fda.gov/cdrh''. The ``Intraocular Lens Guidance Document'' will be available at ``http://www.fda.gov/cdrh/ode/iol-guidance.pds''. IV. Comments Interested persons may, on or before January 12, 2000, submit to Dockets Management Branch (address above) written comments regarding this draft guidance. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The draft guidance and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. Dated: September 29, 1999. Linda S. Kahan, Deputy Director for Regulations Policy, Center for Devices and Radiological Health. [FR Doc. 99-26719 Filed 10-13-99; 8:45 am] BILLING CODE 4160-01-F